Animab key facts
as of Oct 2026- Developer of monoclonal antibodies designed to bring to the market cost-effective services that ultimately benefit animals, producers, and consumers.
- Animab is valued at approximately $16.0M as of Oct 2026 (last reported valuation).
- It has raised $25.4M; the latest was Later Stage VC ($11.5M) in Jul 2025.
- Notable investors include Participatiemaatschappij Vlaanderen, VIB, Agri Investment Fund, Ghent University Endowment, Anacura — 9 tracked in total.
- Status: Privately Held (backing).
Animab's last reported valuation, Nov 2022. Nothing priced has surfaced since.
- ·Watch Animab: the Monday email on marks, rounds and moves
Animab funding rounds
No funding rounds for Animab are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Animab valuation
Animab's last reported valuation was $16 million in Nov 2022. No priced round, secondary trade or fund mark has surfaced since.
Animab investors
9 investors are on record for Animab, including Participatiemaatschappij Vlaanderen, VIB, Agri Investment Fund and Ghent University Endowment.
About Animab
Developer of monoclonal antibodies designed to bring to the market cost-effective services that ultimately benefit animals, producers, and consumers. The company's antibodies utilize proprietary research discoveries to target speed and precision-specific intestinal pathogens in livestock without altering the healthy microbiome, enabling piglets to remain protected during their most fragile post-weaning stage.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Gent, Belgium
- Founded
- 2020
- Employees
- 10
- Website
- animab.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.